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Volume overload is an important clinical target in heart fail-
re (HF) management. Diuretics improve symptoms and exercise
apacity through reduction in volume overload by increases in uri-
ary volume and sodium excretion in patients with HF, although
ts effect on mortality is not well conﬁrmed [1,2]. In the acute stage
f HF, intravenous diuretics such as furosemide or carperitide are
dministered at doses sufﬁcient to optimize circulation volume
nd relieve congestion. However, high doses of loop diuretics are
ssociated with poor prognosis in acute HF, although whether this
nding represents cause or effect has not been clariﬁed [3]. Con-
entional diuretics sometimes induce not only an excessively rapid
eduction in intravascular volume, but also have the potential to
educe glomerular ﬁltration rate, further worsen neuro-humoral
ctivation, and produce electrolyte disturbances. The risk of elec-
rolyte depletion is markedly enhanced when loop diuretics and
hiazides are used in combination. Combination diuretic therapy
sing loop diuretics and thiazides can more than double daily urine
odium excretion to induce weight loss and edema resolution, at
he risk of inducing severe hypokalemia in addition to hypona-
remia, hypotension, and worsening renal function. Hyponatremia
s a signiﬁcant and independent predictor of outcomes including
e-hospitalization and mortality in patients with both acute and
hronic HF [4]. Depletion of potassium and magnesium can predis-
ose patients to serious cardiac arrhythmias.
Recent evidence suggests that vasopressin type 2 receptor
ntagonists induce an increase in urinary volume without signiﬁ-
antly affecting serum potassium, blood pressure, or renal function.
olvaptan (TLV) is a new type of drug that promotes water diuresis
y selectively inhibiting the vasopressin type 2 receptors in col-
ecting tubule [5,6]. In patients hospitalized with volume overload,
ncluding HF, who have persistent severe hyponatremia despite
ater restriction and maximization of conventional diuretics, TLV
hould be considered in the short term to improve serum sodium
oncentration in hypervolemic, hyponatremic states [7]. However,
t is not known whether TLV has supplemental effects to enhance
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ttp://dx.doi.org/10.1016/j.jccase.2013.08.009the natriuresis that loop diuretics induce. By separately control-
ling the renal excretion of water and that of electrolytes, TLV may
allow optimization of diuretic therapy in HF, and perhaps reduce
or minimize the need for loop diuretics.
In this issue of the Journal of Cardiology Cases, Nishizaki et al.
reported that an 82-old female patient with HF due to severe aortic
valve stenosis and cor pulmonale was treated successfully by con-
comitant administration of TLV with furosemide [8]. The patient
had needed ventilator support because of respiratory deteriora-
tion. First, furosemide and spironolactone were administered, and
positive end-expiratory pressure was  introduced during the night.
Then, TLV was chosen because worsening systemic edema and
increased pleural effusion, and advancement of cardiomegaly con-
comitantly with a decrease in potassium. TLV caused an increase in
urine volume, a decrease in body weight, and the pleural effusion.
The patient gradually recovered to be able to stand with gripping
and was  discharged from hospital on day 171 after admission. The
authors speculated that TLV promoted free-water ﬁltration as its
direct effect and sodium ﬁltration as its indirect effect. The mecha-
nism of enhanced diuretic action induced by the concomitant use of
TLV with loop diuretics not only promotes water diuresis, known as
its primary function, but may  also enhance natriuresis induced by
loop diuretics. In addition, by optimizing diuretic therapy through a
speciﬁc effect on water excretion, it might be possible to reduce the
dosage of loop diuretics and thereby limit other side effects asso-
ciated with high doses of loop diuretics such as diminished renal
function.
In the clinical setting, volume overload is usually evaluated by
systemic signs such as pre-tibial edema, pleural effusion, brain
natriuretic peptide, and diameter changes in inferior vena cava
on echocardiography. Authors examined plasma (P) and urine
(U) osmolality (osm) to know a free-water clearance {free-water
clearance = urine volume − (Uosm × urine volume)/(Posm)}. TLV
increases free-water clearance as consequences of an increase
in urine volume and a decrease in urine osmolality. Thus, this
would be the optimal marker to understand whether TLV excretes
water alone without increased electrolyte excretion. Repetitive
serum Na concentration would be needed to avoid hypernatremia.
Udelson et al. [9] reported that TLV monotherapy without concomi-
tant loop diuretic therapy reduced body weight when compared
to placebo without adverse changes in serum electrolytes, dur-
ing sodium-restricted diet on background medications including
angiotensin-converting enzyme inhibitors and beta-blockers. In
the current report, the patient did not receive concomitant admin-
istration of angiotensin-converting enzyme inhibitor, angiotensin
vier Ltd. All rights reserved.
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eceptor blocker, or beta-blocker, because her blood pressure was
ow and she had severe aortic stenosis. On the other hand, it is
eported that TLV has a diuretic effect in patients with severe
hronic kidney diseases [10] and vaptans prevent worsening of
enal function compared to conventional therapy [11]. The key
mplication of the current case report is that TLV might aug-
ent both the diuretic and the natriuretic response to furosemide
ithout adversely affecting hemodynamic variables, neurohor-
ones, renal blood ﬂow, glomerular ﬁltration rate, or electrolytes
n patients with HF. It would need further investigations in a
arger clinical trial to conﬁrm whether TLV enhances the effects
f furosemide.
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